Curi RMB Capital LLC Buys 1,499 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Curi RMB Capital LLC grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 26.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,070 shares of the company's stock after purchasing an additional 1,499 shares during the period. Curi RMB Capital LLC's holdings in IDEXX Laboratories were worth $2,923,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Insight Wealth Strategies LLC boosted its holdings in IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after purchasing an additional 7,041 shares during the period. Sax Wealth Advisors LLC grew its position in IDEXX Laboratories by 76.3% during the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock worth $590,000 after buying an additional 617 shares in the last quarter. Hantz Financial Services Inc. increased its stake in IDEXX Laboratories by 11.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock worth $3,199,000 after acquiring an additional 800 shares during the last quarter. Paragon Capital Management Inc. raised its holdings in shares of IDEXX Laboratories by 25.7% in the 4th quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company's stock valued at $1,579,000 after acquiring an additional 782 shares in the last quarter. Finally, Manitou Investment Management Ltd. grew its holdings in shares of IDEXX Laboratories by 491.0% during the fourth quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company's stock worth $21,582,000 after purchasing an additional 43,369 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.98% of the company's stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of research reports. Piper Sandler boosted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Morgan Stanley cut their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, April 12th. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a report on Monday, April 14th. Finally, Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $523.75.

IDEXX Laboratories Trading Down 0.8 %

IDXX stock traded down $3.54 during trading on Friday, hitting $437.44. 939,265 shares of the company traded hands, compared to its average volume of 632,646. The company has a 50-day moving average of $419.93 and a 200-day moving average of $429.42. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $548.88. The firm has a market capitalization of $35.45 billion, a PE ratio of 41.00, a P/E/G ratio of 3.41 and a beta of 1.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.